In life sciences, where innovation and unpredictability go hand in hand, a straight-line career path is the exception rather ...

EY's Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.

Memo Therapeutics CEO Erik van den Berg reflects on the strategies and skills needed to build company resilience and navigate ...

Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal ...

Life sciences legal departments can do more to improve financial efficiency across an organization. This article includes ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

The Biden administration, through policy and leadership appointments, raised the level of government scrutiny over biopharmaceutical IP and patenting practices. From the FTC’s challenge (under Biden ...

The recent revision of the EU Annex 1 has introduced significant changes that are poised to reshape pharmaceutical manufacturing standards. Dive into insightful discussions with PharmaLex expert ...